<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>Stalin, Jimmy</dc:creator>
  <dc:creator>Coquoz, Oriana</dc:creator>
  <dc:creator>Jeitziner Marcone, Rachel</dc:creator>
  <dc:creator>Jemelin, Stéphane</dc:creator>
  <dc:creator>Desboeufs, Nina</dc:creator>
  <dc:creator>Delorenzi, Mauro</dc:creator>
  <dc:creator>Blot-Chabaud, Marcel</dc:creator>
  <dc:creator>Beat, Imhof</dc:creator>
  <dc:creator>Ruegg, Curzio</dc:creator>
  <dc:date>2023</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">The melanoma cell adhesion molecule, shed from endothelial and cancer cells, is a soluble growth factor that induces tumor angiogenesis and growth. However, the molecular mechanism accounting for its generation in a tumor context is still unclear. To investigate this mechanism, we performed in vitro experiments with endothelial/cancer cells, gene expression analyses on datasets&#13;
from human colorectal tumor samples, and applied pharmacological methods in vitro/ in vivo with mouse and human colorectal cancer cells. We found that soluble MCAM generation is governed by ADAM17 proteolytic activity and NOX1-regulating ADAM17 expression. The treatment of colorectal tumor-bearing mice with pharmacologic NOX1 inhibitors or tumor growth in NOX1-deficient mice reduced the blood concentration of soluble MCAM and abrogated the anti-tumor effects of anti-soluble MCAM antibodies while ADAM17 pharmacologic inhibitors reduced tumor growth and angiogenesis in vivo. Especially, the expression of MCAM, NOX1, and ADAM17 was more prominent in the angiogenic, colorectal cancer-consensus molecular subtype 4 where high MCAM expression correlated with angiogenic and lymphangiogenic markers. Finally, we demonstrated that soluble MCAM also acts as a lymphangiogenic factor in vitro. These results identify a role for NOX1/ADAM17 in soluble MCAM generation, with potential clinical therapeutic relevance to the aggressive, angiogenic CMS4 colorectal cancer subtype.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://folia.unifr.ch/global/documents/327473</dc:identifier>
  <dc:identifier>https://folia.unifr.ch/documents/327473/files/biomedicines-11-03185-1_0.pdf</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.3390/biomedicines11123185</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/issn/2227-9059</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:rights>CC BY</dc:rights>
  <dc:source>Biomedicines. - MDPI AG. - 2023, vol. 11, no. 12, p. 3185</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">NADPH oxidases; melanoma cell adhesion molecule</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">angiogenesis</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">lymphangiogenesis</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">pharmacologic inhibitors</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">colorectal tumor</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">bioinformatic analysis.</dc:subject>
  <dc:subject>info:eu-repo/classification/udc/616</dc:subject>
  <dc:title xmlns:ns7="xml" ns7:lang="en">Targeting of the NOX1/ADAM17 Enzymatic Complex Regulates Soluble MCAM-Dependent Pro-Tumorigenic Activity in Colorectal Cancer</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
